Surgical Ventricular Restoration

Medical Benefit

Effective Date: 04/01/18
Next Review Date: 01/19

Preauthorization

Review Dates: 03/07, 05/08, 05/09, 05/10, 05/11, 05/12, 05/13, 05/14, 01/15, 01/16, 01/17, 01/18

This protocol considers this test or procedure investigational. If the physician feels this service is medically necessary, preauthorization is recommended.

The following protocol contains medical necessity criteria that apply for this service. The criteria are also applicable to services provided in the local Medicare Advantage operating area for those members, unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Please note that payment for covered services is subject to eligibility and the limitations noted in the patient's contract at the time the services are rendered.

### Populations
- Individuals: With ischemic dilated cardiomyopathy

### Interventions
- Interventions of interest are:
  - Surgical ventricular restoration as an adjunct to standard coronary artery bypass grafting

### Comparators
- Comparators of interest are:
  - Coronary artery bypass grafting

### Outcomes
- Relevant outcomes include:
  - Overall survival
  - Symptoms
  - Quality of life
  - Hospitalizations
  - Resource utilization
  - Treatment-related morbidity

### Description

Surgical ventricular restoration (SVR) is designed to restore or remodel the left ventricle to its normal, spherical shape and size in patients with akinetic segments of the heart, secondary to ischemic dilated cardiomyopathy.

### Summary of Evidence

For individuals who have ischemic dilated cardiomyopathy who receive SVR as an adjunct to coronary artery bypass grafting, the evidence includes one large randomized controlled trial (RCT) (another RCT reported results, but most of the patients were included in the larger trial) and uncontrolled studies. Relevant outcomes are overall survival, symptom, quality of life, hospitalizations, resource utilization, and treatment-related morbidity. The RCT, the Surgical Treatment of Ischemic Heart Failure (STICH) trial, did not report significant improvements in quality of life outcomes for patients undergoing SVR as an adjunct to standard coronary artery bypass grafting surgery. Several uncontrolled studies have suggested that SVR can improve hemodynamic functioning in selected patients with ischemic cardiomyopathy; however, these studies are considered lower quality evidence. The evidence is insufficient to determine the effects of the technology on health outcomes.

### Policy

Surgical ventricular restoration is considered investigational for the treatment of ischemic dilated cardiomyopathy.
Policy Guidelines

Surgical ventricular restoration involves increased physician work compared with standard ventriculectomy. For example, the procedure includes evaluation of the ventricular septum and reshaping of the geometry of the heart. Surgical ventricular restoration is described as a global treatment of left ventricular failure, while conventional left ventricular aneurysmectomy represents a local treatment of a transmural infarct.

Background

SVR is also known as surgical anterior ventricular endocardial restoration (SAVER), left ventricular reconstructive surgery, endoventricular circular plasty, or the Dor procedure (named after Vincent Dor, MD). Dr. Dor pioneered the expansion of techniques for ventricular reconstruction and is credited with treating heart failure patients with SVR and coronary artery bypass grafting (CABG).

SVR is usually performed after CABG and may precede or be followed by mitral valve repair or replacement and other procedures such as endocarctectomy and cryoablation for treatment of ventricular tachycardia. A key difference between SVR and ventriculectomy (i.e., for aneurysm removal) is that, in SVR, circular “purse string” suturing is used around the border of the aneurysmal scar tissue. Tightening of this suture is believed to isolate the akinetic or dyskinetic scar, bring the healthy portion of the ventricular walls together, and restore a more normal ventricular contour. If the defect is large (i.e., an opening greater than three cm), the ventricle may also be reconstructed using patches of autologous or artificial material to maintain the desired ventricular volume and contour during closure of the ventriculotomy. In addition, SVR is distinct from partial left ventriculectomy which does not attempt to specifically resect akinetic segments and restore ventricular contour.

Regulatory Status

In 2004, the CorRestore™ Patch System (Somanetics Corp.) was cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process for use “as an intracardiac patch for cardiac reconstruction and repair.” The device consists of an oval tissue patch made from glutaraldehyde-fixed bovine pericardium. It is identical to other marketed bovine pericardial patches, except that it incorporates an integral suture bolster in the shape of a ring that is used along with ventricular sizing devices to restore the normal ventricular contour. FDA product code: DXZ.

Services that are the subject of a clinical trial do not meet our Technology Assessment Protocol criteria and are considered investigational. For explanation of experimental and investigational, please refer to the Technology Assessment Protocol.

It is expected that only appropriate and medically necessary services will be rendered. We reserve the right to conduct prepayment and postpayment reviews to assess the medical appropriateness of the above-referenced procedures. Some of this protocol may not pertain to the patients you provide care to, as it may relate to products that are not available in your geographic area.

References

We are not responsible for the continuing viability of web site addresses that may be listed in any references below.